MedDataX Logo

Frequency of Tuberculosis in Psoriasis Patients

NCT ID: NCT06563635

Last Updated: 2024-08-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

719 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-05-01

Study Completion Date

2023-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aim of this study is evaluation of patients receiving TNF inhibitor therapy in terms of tuberculosis at the end of 15 years in a single center.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Effectiveness and Safety of Tumor Necrosis Factor (TNF) Inhibitors in Patients With Moderate to Severe Psoriasis

NCT01126619

Psoriasis
COMPLETED

Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis

NCT05344482

Plaque Psoriasis
COMPLETED

A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis

NCT07234591

Plaque Psoriasis Moderate to Severe Plaque Psoriasis
RECRUITING NA

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03536884

Chronic Plaque Psoriasis Moderate to Severe Chronic Plaque Psoriasis
COMPLETED PHASE3

TAB08 in Patients With Psoriasis Vulgaris, Not Adequately Controlled With Current Treatment

NCT02796053

Psoriasis Vulgaris
COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Aim of this study is evaluation of patients receiving TNF inhibitor therapy in terms of tuberculosis at the end of 15 years in a single center. TNF inhibitor therapy may increase the risk for tuberculosis infection. According to medical data in our hospital in last 15 years, tuberculosis rate of psoriasis patients receiving etanercept, adalimumab and infliximab will be compared.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis Vulgaris Tuberculosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

etanercept

psoriasis patients receiving etanercept therapy

No interventions assigned to this group

infliximab

psoriasis patients receiving infliximab therapy

No interventions assigned to this group

adalimumab

psoriasis patients receiving adalimumab therapy

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* psoriasis patients receiving TNF inhibitor therapy

Exclusion Criteria

* patients without TNF inhibitor therapy
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bezmialem Vakif University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Bezmialem Vakif University Hospital

Istanbul, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

E-54022451-050.05.04-116589

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Assessment of Efficacy and Safety of Secukinumab in Adult Patients in Turkish Population
NCT02795416 WITHDRAWN PHASE3
Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis
NCT02595970 COMPLETED PHASE3
Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
NCT03066609 COMPLETED PHASE3
Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions
NCT03629379 COMPLETED PHASE4
A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis
NCT06952465 ACTIVE_NOT_RECRUITING
Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT05335356 COMPLETED PHASE3
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis
NCT03230292 COMPLETED PHASE2
Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis
NCT04453137 COMPLETED PHASE3
Characterization of the Fungal Immunopeptidome Involved in the Immunopathological Mechanisms of Psoriasis
NCT06610942 NOT_YET_RECRUITING
Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis
NCT01090063 COMPLETED NA
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
NCT02931838 COMPLETED PHASE2
Study of Psoriatic Arthritis
NCT00001420 COMPLETED
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT02850965 COMPLETED PHASE3
Randomized Double-Blind Placebo-Controlled Trial Using Recombinant Human Interleukin-10 for Moderate-to-Severe Psoriasis
NCT00001797 COMPLETED PHASE2
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
NCT06506916 RECRUITING PHASE3
Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers
NCT02362789 COMPLETED PHASE3
A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)
NCT02394561 COMPLETED PHASE3
Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis
NCT01736696 COMPLETED PHASE1
Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment
NCT04632927 COMPLETED PHASE3
The Impact of Targeted Therapy on Microorganism in Patients With Psoriasis
NCT01504113 UNKNOWN
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT03598790 COMPLETED PHASE3
Efficacy and Safety Evaluation of Anti-CD20 Monoclonal Antibody Combined with Azathioprine and Corticosteroids in the Treatment of Pemphigus Vulgaris
NCT06654817 COMPLETED
A Study to Evaluate the Efficacy and Safety of LZM012
NCT06110676 UNKNOWN PHASE3
Regulation of Inflammatory Genes in Psoriasis
NCT03125655 RECRUITING
A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece
NCT02713295 COMPLETED